Who are Bupivacaine 0.167%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bupivacaine Liposomes(BL), ESL, intraarticular injection with ropivacaine, Control (bupivacaine), Exparel/bupivacaine mixture, lamotrigine (generic Teva).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupivacaine-0-167.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bupivacaine 0.167% — Competitive Intelligence Brief

Bupivacaine 0.167% (Bupivacaine 0.167%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine 0.167% (Bupivacaine 0.167%) — Bozyaka Training and Research Hospital. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bupivacaine 0.167% TARGET	Bupivacaine 0.167%	Bozyaka Training and Research Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine Liposomes(BL)	Bupivacaine Liposomes(BL)	Huazhong University of Science and Technology	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
ESL	ESL	Bial - Portela C S.A.	marketed	Voltage-gated sodium channel blocker; anticonvulsant	Voltage-gated sodium channels (Nav)
intraarticular injection with ropivacaine	intraarticular injection with ropivacaine	Hvidovre University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Control (bupivacaine)	Control (bupivacaine)	Kasr El Aini Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

University of California, San Diego · 3 drugs in this class
Durect · 3 drugs in this class
Pacira Pharmaceuticals, Inc · 3 drugs in this class
Wake Forest University Health Sciences · 3 drugs in this class
Medical University of Vienna · 3 drugs in this class
Imperial College London · 2 drugs in this class
Hvidovre University Hospital · 2 drugs in this class
Innocoll · 2 drugs in this class
George Washington University · 2 drugs in this class
Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine 0.167% — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-0-167. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab